ImmuronASX:IMC -2.86% EBITDA Margin % is -45.70% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Immuron ranks better than 50.74% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Immuron's EBITDA for the
six
months ended in Dec. 2025 was A$-1.91 Mil. Immuron's Revenue for the
six
months ended in Dec. 2025 was A$4.18 Mil. Therefore, Immuron's EBITDA margin for the quarter that ended in Dec. 2025 was -45.70%.
Immuron (ASX:IMC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Immuron EBITDA Margin % Related Terms
Immuron EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Immuron's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IMC vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Immuron's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Immuron's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron (ASX:IMC) has a EBITDA Margin % of -45.70% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Immuron and its competitors. According to the industry distribution chart, Immuron ranks #465 out of 944 companies in the Biotechnology industry, placing it in the top 49.3%.
Is Immuron's EBITDA Margin % too high?
Immuron's current EBITDA Margin % is -45.70%. Based on the distribution chart, Immuron ranks #465 out of 944 companies in the Biotechnology industry, which is above the industry midpoint.
How does Immuron's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #465 out of 944 companies for EBITDA Margin %. This puts Immuron in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Immuron and its competitors. Immuron's current EBITDA Margin % is -45.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Based on GuruFocus' analysis, Immuron (ASX:IMC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.03 — trading 85.2% below its estimated fair value. The current EBITDA Margin % is -45.70%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Immuron (ASX:IMC), the current EBITDA Margin % is -45.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMC has been successfully added to your 